Thales Prepares to Secure European Infrastructures Against Attacks From Future Quantum Computers
14.4.2023 15:03:00 EEST | Business Wire | Press release
As a driving force in the second quantum revolution, Thales has joined forces with around twenty deep tech, academic and industry partners, as part of the EuroQCI initiative (European Quantum Communication Infrastructure), which aims to deploy a quantum communication infrastructure for EU member states within three years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230414005211/en/
©Carlos Castilla
By 2040, quantum computers could use their unprecedented computational power to decode encrypted data, incomparably threatening the security of even the best-protected communication systems. EuroQCI aims to counter that threat by developing sovereign systems to protect the communications and data assets of critical infrastructure providers and government institutions.
The longer-term objective of the initiative is to create a Quantum Information Network (QIN) that will harness the phenomenon of quantum entanglement not only to guarantee communications security but also to create networks of quantum sensors and processors, which have the potential to drive exponential increases in the already outstanding performance of quantum sensors and quantum computers.
As part of this effort, today, Thales is breaking new ground as a member of multiple new consortia that have been set up since late 2022 in these domains:
- Quantum repeaters, with the Delft University: QIA (Quantum Internet Alliance) – led by the Delft University of Technology in the Netherlands – is working to demonstrate the feasibility of connecting users in two metropolitan areas 500 km apart, using quantum repeaters, which can compensate for the loss of information via a quantum memory;
- Quantum key distribution: QKISS – coordinated by Exail – and QUARTER – led by LuxQuanta – are developing Quantum Key Distribution systems to protect users' critical communications from cyberattacks.
- Certification of quantum communication: PETRUS – led by Deutsche Telekom – is the official coordinator of 32 EuroQCI projects, on behalf of the European Commission. It is also developing a framework for certification and accreditation of quantum communication products and networks.
- Satellites quantum communications: TeQuantS – led by Thales Alenia Space – aims at developing quantum space-to-Earth communications technologies, necessary for cybersecurity applications and future quantum information networks, through the construction of satellites and optical ground stations by the end of 2026.
Specifically, the Thales teams taking part in these projects are working to develop quantum key generation, distribution and management equipment and the associated communication encryption devices, as well as defining the architecture of these quantum communication infrastructures.
Thales operates the largest quantum physics research facilities in Europe, in partnership with the CNRS, and some 100 engineers and researchers are currently engaged in the development of the quantum solutions (sensors, communications and algorithms) that will play a foundational role in tomorrow's world. These new consortia will all benefit from Thales's multi-disciplinary expertise, in particular in the field of secure communication networks.
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005211/en/
Contact information
PRESS
Thales, Media Relations
Philomène Emptaz
philomene.emptaz@thalesgroup.com
06. 59. 06. 98. 76
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
